Biological Products, (No Diagnostic Substances) · Nasdaq
For the period ended December 31, 2025, AMGEN INC reported $36.8 billion across 2 reportable segments: Product sales ($35.15B, 95.6%), Other revenues ($1.60B, 4.4%). Product sales's share of the total is up from 95.0% for the period ended December 31, 2019.
For the period ended December 31, 2025, AMGEN INC reported $36.8 billion across 2 geographies: U.S. ($26.42B, 71.9%), ROW ($10.33B, 28.1%). U.S.'s share of the total is down from 73.7% for the period ended December 31, 2019.
AMGEN INC annual revenue by reportable segment, as disclosed in SEC filings.
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| Product sales | $24.30B | $24.80B | $26.91B | $32.03B | $35.15B | 95.6% |
| Other revenues | $1.68B | $1.52B | $1.28B | $1.40B | $1.60B | 4.4% |
| Total | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
AMGEN INC annual revenue by geography, as disclosed in SEC filings.
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share |
|---|---|---|---|---|---|---|
| U.S. | $18.19B | $18.59B | $19.81B | $23.86B | $26.42B | 71.9% |
| ROW | $7.79B | $7.73B | $8.38B | $9.56B | $10.33B | 28.1% |
| Total | $25.98B | $26.32B | $28.19B | $33.42B | $36.75B |
Extracted from the XBRL segment tags in the company’s SEC filings. Figures are as reported and are not restated or adjusted.
Data: SEC EDGAR (financials, KPIs, segments) · Yahoo Finance (price, splits, metrics, analyst estimates, news headlines). Not financial advice.